WO2006039630A3 - Materials and methods for identifying compounds that modulate the cell cycle - Google Patents

Materials and methods for identifying compounds that modulate the cell cycle Download PDF

Info

Publication number
WO2006039630A3
WO2006039630A3 PCT/US2005/035448 US2005035448W WO2006039630A3 WO 2006039630 A3 WO2006039630 A3 WO 2006039630A3 US 2005035448 W US2005035448 W US 2005035448W WO 2006039630 A3 WO2006039630 A3 WO 2006039630A3
Authority
WO
WIPO (PCT)
Prior art keywords
levels
molecules
cyclin
type
materials
Prior art date
Application number
PCT/US2005/035448
Other languages
French (fr)
Other versions
WO2006039630A2 (en
Inventor
Loren J Field
Original Assignee
Univ Indiana Res & Tech Corp
Loren J Field
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Indiana Res & Tech Corp, Loren J Field filed Critical Univ Indiana Res & Tech Corp
Publication of WO2006039630A2 publication Critical patent/WO2006039630A2/en
Publication of WO2006039630A3 publication Critical patent/WO2006039630A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders

Abstract

D-type cyclin including D1, D2 and D3 are shown to be actively involved in the regulation of cardiomyocyte cell growth and proliferation. The levels of the various cyclins including the relative levels of these three cyclins have varying effects on the growth of cardiomyocytes. Type-D cyclin levels vary with response to various stimuli including injury effects D-type cyclin levels and localization within cardiomyocytes. Various methods, materials and systems for screening for candidate molecules that may effect D-type cyclin levels including molecules that may affect the expression, stability and/or subcellular location or other aspects of one or more of the cyclin D proteins are described. Various types of molecules including RNAi, small molecules, proteins, nucleic acids, and the like can be screened to identify candidate molecules.
PCT/US2005/035448 2004-10-02 2005-10-02 Materials and methods for identifying compounds that modulate the cell cycle WO2006039630A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61555804P 2004-10-02 2004-10-02
US60/615,558 2004-10-02
US62867704P 2004-11-16 2004-11-16
US60/628,677 2004-11-16
US63384904P 2004-12-07 2004-12-07
US60/633,849 2004-12-07

Publications (2)

Publication Number Publication Date
WO2006039630A2 WO2006039630A2 (en) 2006-04-13
WO2006039630A3 true WO2006039630A3 (en) 2009-04-09

Family

ID=36143132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035448 WO2006039630A2 (en) 2004-10-02 2005-10-02 Materials and methods for identifying compounds that modulate the cell cycle

Country Status (1)

Country Link
WO (1) WO2006039630A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962409B2 (en) 2007-10-01 2018-05-08 Vestion, Inc. Therapy using cardiac stem cells and mesenchymal stem cells
WO2010094757A1 (en) * 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Use of primary human cardiomyocytes
WO2010094694A1 (en) * 2009-02-23 2010-08-26 F. Hoffmann-La Roche Ag Assays to predict cardiotoxicity
EP2925863B1 (en) 2012-11-30 2020-07-15 Vestion Inc. Cardiac stem cells and methods of identifying and using the same
WO2015066197A2 (en) 2013-10-29 2015-05-07 Vestion, Inc. Cardiac neural crest cells and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020166134A1 (en) * 1999-06-18 2002-11-07 Field Loren J. Cardiomyocytes with enhanced proliferative potenial, and methods for preparing and using same
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737241B2 (en) * 1996-01-23 2004-05-18 Rigel Pharmaceuticals, Inc. Methods for screening for transdominant intracellular effector peptides and RNA molecules
US20020166134A1 (en) * 1999-06-18 2002-11-07 Field Loren J. Cardiomyocytes with enhanced proliferative potenial, and methods for preparing and using same

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARSENIJEVIC T. ET AL.: "A novel partner for D-type cyclins: protein kinase A-anchorin protein AKAP95", BIOCHEMICAL JOURNAL, vol. 378, 3 January 2004 (2004-01-03), pages 673 - 679, XP003001752 *
HIRAI ET AL., MOLECULAR AND CELLULAR BIOLOGY, vol. 16, 1996, pages 6457 - 6467, XP002040082 *
TAMAMORI-ADACHI ET AL., CIRCULATION RESEARCH, 12 February 2002 (2002-02-12), pages E12 - E19, XP003001759 *
WULF ET AL., THE EMBO JOURNAL, vol. 20, 2001, pages 3459 - 3472, XP002276442 *
ZHOU Y. ET AL., PLANTA, vol. 216, 2003, pages 604 - 613, XP002988803 *

Also Published As

Publication number Publication date
WO2006039630A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
Makhija et al. Nuclear deformability and telomere dynamics are regulated by cell geometric constraints
White et al. Long-lived binding of Sox2 to DNA predicts cell fate in the four-cell mouse embryo
Lagerlöf et al. O-GlcNAc transferase regulates excitatory synapse maturity
Buxboim et al. Matrix elasticity regulates lamin-A, C phosphorylation and turnover with feedback to actomyosin
Montaño et al. Measuring cell-type specific differential methylation in human brain tissue
Peric-Hupkes et al. Role of the nuclear lamina in genome organization and gene expression
Hartmuth et al. Fission yeast Tor1 functions as part of TORC1 to control mitotic entry through the stress MAPK pathway following nutrient stress
WO2017070633A3 (en) Evolved cas9 proteins for gene editing
WO2006039630A3 (en) Materials and methods for identifying compounds that modulate the cell cycle
ATE553192T1 (en) A DNA TARGET SEQUENCE SEPARATING MEGANUCLEASE VARIANTS FROM A XERODERMA PIGMENTOSUM GENE AND THE USE THEREOF
Pawlowski The new micro-kingdoms of eukaryotes
WO2006119239A3 (en) System and method for generating and evaluating an innovation
ATE532857T1 (en) A DNA TARGET SEQUENCE OF MOUSE ROSA26 LOCUS SEPARATING MEGANUCLEASE VARIANTS AND THEIR USE
WO2007065025A3 (en) Method of dna analysis using micro/nanochannel
ATE448258T1 (en) ATTACHMENT OF MOLECULES TO SURFACES
ATE521695T1 (en) CIRCULAR DNA MOLECULE HAVING A CONDITIONAL REPLICATION ORIGIN, METHOD FOR PRODUCING THEREOF AND THEIR USE IN GENE THERAPY
EP2450456A3 (en) Assessment of oocyte competence
Nance et al. Gastrulation in C. elegans
DE69739898D1 (en) TESTING FOR PROTEIN KINAS WITH FLUORESCENT PROTEIN SUBSTRATES
EP4234723A3 (en) Enhancement of cancer screening using cell-free viral nucleic acids
WO2009151757A3 (en) Method and apparatus for forensic screening
WO2007085923A8 (en) Novel fluorescent proteins and methods for using same
WO2014088830A3 (en) Screening of nucleic acid agents via particle display
EP1491894A3 (en) Method for the determination of cell activation
Ma et al. Genetic control of nucleolar size: An evolutionary perspective

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05812293

Country of ref document: EP

Kind code of ref document: A2